"We are very pleased to have Ferring as our partner, given the strength oftheir European specialty urology and endocrinology franchises, theirexisting commercial infrastructure across Europe, and the successful trackrecord they have established in commercializing differentiated products inthe European Union," said Armando Anido, Chief Executive Officer andPresident of Auxilium. "This agreement enables us to bring our innovativetestosterone replacement product to patients in all of the 15 countrieswhere Testim has been approved and potentially in additional new countrieswithin Europe, thus expanding the reach of our Testim franchise outside theUnited States."

"Testim will be an excellent complement to our urology portfolio, where wealready have Minirin® for primary nocturnal enuresis and hope to receiveapproval for our prostate cancer treatment, degarelix, in the first half ofnext year," commented Ferring's Chief Operating Officer, Michel Pettigrew."It is a great pleasure to have cemented this partnership with Auxilium,with whom we share a commitment to the field of urology and a strong focuson patients."

Under the agreement, Auxilium will be responsible for manufacturing andsupplying Testim to Ferring, while Ferring will be responsible for allregulatory, sales, marketing and distribution activities in Europe. Underthe agreement with Ferring, Auxilium will receive a combination of upfront,milestone and royalty payments. Financial details of the agreement were notdisclosed. Testim is currently approved for sale in 15 countries in Europe.The Company and Ipsen Pharma GmbH recently agreed to mutually terminatetheir distribution agreement for Testim in Europe and other countriesoutside North America and Japan.

About Testim

Testim is a novel, topical gel formulation that normalizes low levels oftestosterone in men with hypogonadism, a condition that occurs when a man'sbody does not produce adequate amounts of testosterone. Men withhypogonadism or androgen deficiency may suffer from a decrease in energy,reduced muscle mass, an increase in abdominal fat, decline in libido,decreased sexual function, anemia, fatigue, depression and reduced bonedensity that may result in an increased risk of osteoporosis.

Testim was developed by Auxilium using a proprietary technology licensedfrom CPEX Pharmaceuticals, Inc. (NASDAQ: CPEX), and was launched in theU.S. by Auxilium's sales force in the first quarter of 2003. Auxiliumreceived its first European regulatory approval for Testim in the UK in2003 and currently has regulatory approval in 15 countries in Europethrough the Mutual Recognition Procedure.

About Hypogonadism

A 2006 study that was published in The International Journal of ClinicalPractice showed 39% of men over 45 years of age have low testosterone(total testosterone levels below 300 ng / dL). Hypogonadism is defined asreduced or absent secretion of testosterone which can lead to symptoms suchas loss of libido, adverse changes in body composition, irritability andpoor concentration. Auxilium research estimates that approximately 10% ofmen with hypogonadism currently receive TRT and that this low diagnosisrate stems primarily from low patient and physician awareness of thesymptoms, treatment options and monitoring requirements

About Ferring Pharmaceuticals

Ferring is a Swiss-based, research driven, specialty biopharmaceuticalgroup active in global markets. The company identifies, develops andmarkets innovative products in the areas of urology, gastroenterology, andinfertility. In recent years Ferring has expanded beyond its traditionalEuropean base and now has offices in 45 countries. To learn more aboutFerring or our products please visit http://www.ferring.com.

About Auxilium

Auxilium Pharmaceuticals, Inc. is a specialty biopharmaceutical companywith a focus on developing and marketing to urologists, endocrinologists,orthopedists and select primary care physicians. Auxilium markets Testim®1%, a topical testosterone gel, for the treatment of hypogonadism throughits approximately 190-person sales and marketing team. Auxilium has fiveprojects in clinical development. XIAFLEX™ (clostridial collagenase forinjection), formerly referred to as AA4500, is in phase III of developmentfor the treatment of Dupuytren's contracture and is in phase II ofdevelopment for the treatment of Peyronie's disease and Frozen Shouldersyndrome (Adhesive Capsulitis). Auxilium's transmucosal film productcandidate for the treatment of overactive bladder (AA4010) is in phase I ofdevelopment. The Company is currently seeking a partner to further developthis product candidate. Auxilium also has one pain product (fentanyl) usingits transmucosal film delivery system in phase I of development. Auxiliumhas rights to seven additional pain products and products for hormonereplacement and urologic disease using its transmucosal film deliverysystem. Auxilium also has options to all indications using XIAFLEX fornon-topical formulations. For additional information, visithttp://www.auxilium.com.

SAFE HARBOR STATEMENT UNDER THE PRIVATE SECURITIES LITIGATION REFORM ACT OF1995

This release contains "forward-looking-statements" within the meaning ofThe Private Securities Litigation Reform Act of 1995, including, but notlimited to, statements regarding the size of the market for Testim, thesales of Testim by Ferring in Europe, the effect of the distributionagreement with Ferring on the Company's revenues, the ability of Ferring tofulfill its obligations under the distribution agreement, and products indevelopment for the treatment of Dupuytren's contracture, Peyronie'sdisease, Frozen Shoulder syndrome, overactive bladder and pain. Allstatements other than statements of historical facts contained in thisrelease, including but not limited to, statements regarding futureexpectations, plans and prospects for the Company, financial guidance andother statements containing the words "believe," "may," "could," "will,""estimate," "continue," "anticipate," "intend," "should," "plan," "expect,"and similar expressions, as they relate to the Company, constituteforward-looking statements. Actual results may differ materially from thosereflected in these forward-looking statements due to various factors,including general financial, economic, regulatory and political conditionsaffecting the biotechnology and pharmaceutical industries and thosediscussed in the Company's Annual Report on Form 10-K for the period endedDecember 31, 2007 and the Company's Quarterly Report on Form 10-Q for theperiod ended September 30, 2008 under the heading "Risk Factors," which areon file with the Securities and Exchange Commission (the "SEC") and may beaccessed electronically by means of the SEC's home page on the Internet athttp://www.sec.gov or by means of the Company's home page on the Internetat http://www.auxilium.com under the heading "Investor Relations - SECFilings." There may be additional risks that the Company does not presentlyknow or that the Company currently believes are immaterial which could alsocause actual results to differ from those contained in the forward-lookingstatements. Given these risks and uncertainties, any or all of theseforward-looking statements may prove to be incorrect. Therefore, you shouldnot rely on any such factors or forward-looking statements.

In addition, forward-looking statements provide the Company's expectations,plans or forecasts of future events and views as of the date of thisrelease. The Company anticipates that subsequent events and developmentswill cause the Company's assessments to change. However, while the Companymay elect to update these forward-looking statements at some point in thefuture, the Company specifically disclaims any obligation to do so. Theseforward-looking statements should not be relied upon as representing theCompany's assessments as of any date subsequent to the date of thisrelease.

CONTACT:Auxilium PharmaceuticalsJames E. FickenscherChief Financial OfficerAuxilium Pharmaceuticals, Inc.+1-484-321-5900Email ContactWilliam Q. Sargent Jr.Vice-President, Investor Relations and Corporate Communications+1-484-321-5900Email ContactFerring PharmaceuticalsMichael GeorgeSenior Corporate Communications Manager+41 58 301 0053Email Contact